Related Experiment Video
Updated: May 9, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies
Andrei Turtoi1, Arnaud Blomme, Delphine Debois
1Metastasis Research Laboratory, GIGA Cancer, University of Liège, Liège, Belgium; Mass Spectrometry Laboratory, GIGA Research, University of Liège, Liège, Belgium.
Unlabelled:
Tumor heterogeneity is a major obstacle for developing effective anticancer treatments. Recent studies have pointed to large stochastic genetic heterogeneity within cancer lesions, where no pattern seems to exist that would enable a more structured targeted therapy approach. Because to date no similar information is available at the protein (phenotype) level, we employed matrix assisted laser desorption ionization (MALDI) image-guided proteomics and explored the heterogeneity of extracellular and membrane subproteome in a unique collection of eight fresh human colorectal carcinoma (CRC) liver metastases. Monitoring the spatial distribution of over 1,000 proteins, we found unexpectedly that all liver metastasis lesions displayed a reproducible, zonally delineated pattern of functional and therapeutic biomarker heterogeneity. The peritumoral region featured elevated lipid metabolism and protein synthesis, the rim of the metastasis displayed increased cellular growth, movement, and drug metabolism, whereas the center of the lesion was characterized by elevated carbohydrate metabolism and DNA-repair activity. From the aspect of therapeutic targeting, zonal expression of known and novel biomarkers was evident, reinforcing the need to select several targets in order to achieve optimal coverage of the lesion. Finally, we highlight two novel antigens, LTBP2 and TGFBI, whose expression is a consistent feature of CRC liver metastasis. We demonstrate their in vivo antibody-based targeting and highlight their potential usefulness for clinical applications.
Conclusion:
The proteome heterogeneity of human CRC liver metastases has a distinct, organized pattern. This particular hallmark can now be used as part of the strategy for developing rational therapies based on multiple sets of targetable antigens.
Insights
Tumor heterogeneity in colorectal cancer liver metastases shows an organized protein pattern. This discovery enables developing targeted therapies using multiple biomarkers for improved treatment strategies.
Area of Science:
- Proteomics
- Cancer Biology
- Metastasis Research
Background:
- Tumor heterogeneity poses a significant challenge to effective cancer treatment.
- Genetic heterogeneity in tumors often lacks discernible patterns for targeted therapy.
- Limited information exists on protein-level heterogeneity in tumors.
Purpose of the Study:
- To explore the heterogeneity of extracellular and membrane subproteomes in human colorectal carcinoma (CRC) liver metastases.
- To identify spatial patterns of protein expression and their functional implications.
- To assess the potential for developing novel therapeutic targets based on proteomic patterns.
Main Methods:
- Matrix assisted laser desorption ionization (MALDI) image-guided proteomics.
- Analysis of extracellular and membrane subproteomes in eight human CRC liver metastases.
- Spatial distribution monitoring of over 1,000 proteins.
Main Results:
- Discovered a reproducible, zonally delineated pattern of functional and therapeutic biomarker heterogeneity across all liver metastases.
- Identified distinct metabolic and activity profiles in the peritumoral, rim, and center regions of metastases.
- Revealed zonal expression of known and novel biomarkers, including LTBP2 and TGFBI, suitable for therapeutic targeting.
Conclusions:
- Proteome heterogeneity in human CRC liver metastases exhibits an organized, zonal pattern.
- This organized pattern can guide the development of rational therapies targeting multiple antigens.
- Novel antigens LTBP2 and TGFBI show potential for clinical application in CRC liver metastasis treatment.

